PRAME and acute promyelocytic leukemia: In acute promyelocytic leukaemia (APL) patients who harbour the t(15;17) translocation, had a decreased expression of Preferentially Expressed Antigen In Melanoma (PRAME) that correlated with a shorter overall survival [69], whereas the typically favourable t(8;21) translocation was associated with a higher level of PRAME in AML M2 patients [70].